Medication overuse headache

Headache

Volumn 54, Issue 7, 2014, Pages 1251-1257

  Munksgaard, Signe B ^a   Jensen, Rigmor H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

medication overuse headache; pathophysiology of medication overuse headache; prophylactic medication; treatment of medication overuse headache

Indexed keywords

ANALGESIC AGENT; ERGOT DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; SEROTONIN; TRIPTAN DERIVATIVE;

ANXIETY DISORDER; CHEMOPROPHYLAXIS; CHRONIC DAILY HEADACHE; CHRONIC PAIN; COMORBIDITY; DEPRESSION; DETOXIFICATION; DRUG INDUCED HEADACHE; HUMAN; IATROGENIC DISEASE; NEUROIMAGING; NEUROPATHOLOGY; NOCICEPTION; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT INFORMATION; PREVALENCE; PRIMARY HEADACHE; PRIORITY JOURNAL; REVIEW; SENSITIZATION; SEROTONIN METABOLISM; TREATMENT WITHDRAWAL; HEADACHE DISORDERS, SECONDARY; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

ANALGESICS; HEADACHE DISORDERS, SECONDARY; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 84904473781     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12408     Document Type: Review

References (90)

1. Diener HC, Limmroth V,. Medication-overuse headache: A worldwide problem. Lancet Neurol. 2004; 3: 475-483. (Pubitemid 38903098)
2. Paemeleire K, Evers S, Goadsby PJ,. Medication-overuse headache in patients with cluster headache. Curr Pain Headache Rep. 2008; 12: 122-127. (Pubitemid 351516399)
3. Willer L, Jensen RH, Juhler M,. Medication overuse as a cause of chronic headache in shunted hydrocephalus patients. J Neurol Neurosurg Psychiatry. 2010; 81: 1261-1264.
4. Horton BT, Peters GA,. Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: Report of 52 cases. Headache. 1963; 2: 214-227.
5. Peters GA, Horton BT,. Headache; with special reference to the excessive use of ergotamine tartrate and dihydroergotamine. J Lab Clin Med. 1950; 36: 972-973.
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988; 8 (Suppl. 7): 1-96.
7. Headache Classification Committee of the International Headache Society. ICHD-II. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24: 9-160.
8. Olesen J, Bousser M-G, Diener H-C, etal. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006; 26: 742-746.
9. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33: 629-808.
10. Stovner LJ, Andree C,. Prevalence of headache in Europe: A review for the Eurolight project. J Headache Pain. 2010; 11: 289-299.
11. Stovner L, Hagen K, Jensen R, etal. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007; 27: 193-210. (Pubitemid 46354128)
12. Evers S, Jensen R,. Treatment of medication overuse headache-Guideline of the EFNS headache panel. Eur J Neurol. 2011; 18: 1115-1121.
13. Evers S, Marziniak M,. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010; 9: 391-401.
14. Linde M, Gustavsson A, Stovner LJ, etal. The cost of headache disorders in Europe: The Eurolight project. Eur J Neurol. 2012; 19: 703-711.
15. Hagen K, Linde M, Steiner TJ, Stovner LJ, Zwart J-A,. Risk factors for medication-overuse headache: An 11-year follow-up study. The Nord-Trøndelag Health Studies. Pain. 2012; 153: 56-61.
16. Jonsson P, Linde M, Hensing G, Hedenrud T,. Sociodemographic differences in medication use, health-care contacts and sickness absence among individuals with medication-overuse headache. J Headache Pain. 2012; 13: 281-290.
17. Diener HC, Silberstein SD,. Medication overuse headache. In:, Olesen J, Goadsby PJ, Ramadan N, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 971-979.
18. Zebenholzer K, Thamer M, Wöber C,. Quality of life, depression, and anxiety 6 months after inpatient withdrawal in patients with medication overuse headache: An observational study. Clin J Pain. 2012; 28: 284-290.
19. Colás R, Muñoz P, Temprano R, Gõmez C, Pascual J,. Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life. Neurology. 2004; 62: 1338-1342. (Pubitemid 38526046)
20. Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M,. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain. 2005; 9: 285-291. (Pubitemid 40615709)
21. Da Silva A, Costa EC, Gomes JB, etal. Chronic headache and comorbibities: A two-phase, population-based, cross-sectional study. Headache. 2010; 50: 1306-1312.
22. Lucas C, Lanteri-Minet M, Massiou H, etal. Headache Clinics-Organization, Patients and Treatment, 1st edn. New York: Oxford University Press; 2007: 89-95.
23. Rossi P, Faroni JV, Nappi G,. Medication overuse headache: Predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008; 28: 1196-1200.
24. Radat F, Lanteri-Minet M,. What is the role of dependence-related behavior in medication-overuse headache? Headache. 2010; 50: 1597-1611.
25. Corbelli I, Caproni S, Eusebi P, Sarchielli P,. Drug-dependence behaviour and outcome of medication-overuse headache after treatment. J Headache Pain. 2012; 13: 653-660.
26. Grande RB, Aaseth K, Saltyte BJ, Gulbrandsen P, Russell MB, Lundqvist C,. The severity of dependence scale detects people with medication overuse: The Akershus study of chronic headache. J Neurol Neurosurg Psychiatry. 2009; 80: 784-789.
27. Lundqvist C, Grande RB, Aaseth K, Russell MB,. Dependence scores predict prognosis of medication overuse headache: A prospective cohort from the Akershus study of chronic headache. Pain. 2012; 153: 682-686.
28. Relja G, Granato A, Bratina A, Antonello RM, Zorzon M,. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia. 2006; 26: 589-595.
29. Rapoport A, Sheftell FD, Weeks RE, Baskin SM, Verdi J,. The "analgesic washout period": A critical variable in the evaluation of headache treatment efficacy. Headache. 1986; 36: 100-101.
30. Rabe K, Pageler L, Gaul C, etal. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2012; 33: 202-207.
31. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V,. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57: 1694-1698. (Pubitemid 33055491)
32. Grande RB, Aaseth K, Benth JŠ, Lundqvist C, Russell MB,. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011; 18: 129-137.
33. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G,. Advice alone vs. structured detoxification programmes for medication overuse headache: A prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006; 26: 1097-1105. (Pubitemid 44199401)
34. Rossi P, Faroni JV, Nappi G,. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol. 2011; 18: 396-401.
35. Zeeberg P, Olesen J, Jensen R,. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006; 26: 1192-1198. (Pubitemid 44359339)
36. Rossi P, Jensen R, Nappi G, Allena M,. A narrative review on the management of medication overuse headache: The steep road from experience to evidence. J Headache Pain. 2009; 10: 407-417.
37. Olesen J,. Detoxification for medication overuse headache is the primary task. Cephalalgia. 2012; 32: 420-422.
38. Diener HC,. Detoxification for medication overuse headache is not necessary. Cephalalgia. 2011; 32: 423-427.
39. Hagen K, Albretsen C, Vilming ST, etal. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia. 2009; 29: 221-232.
40. Aurora SK, Dodick DW, Turkel CC, etal. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793-803.
41. Diener HC, Dodick DW, Aurora SK, etal. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804-814.
42. Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, etal. Medication overuse headache: Clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007; 27: 1219-1225. (Pubitemid 47631900)
43. Munksgaard SB, Bendtsen L, Jensen RH,. Treatment-resistant medication overuse headache can be cured. Headache. 2012; 52: 1120-1129.
44. Munksgaard SB, Bendtsen L, Jensen RH,. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012; 32: 834-844.
45. Negro A, Martelletti P,. Chronic migraine plus medication overuse headache: Two entities or not? J Headache Pain. 2011; 12: 593-601.
46. Altieri M, Di Giambattista R, Di Clemente L, etal. Combined pharmacological and short-term psychodynamic psychotherapy for probable medication overuse headache: A pilot study. Cephalalgia. 2009; 29: 293-299.
47. Grazzi L, Usai S, Prunesti A, Bussone G, Andrasik F,. Behavioral plus pharmacological treatment versus pharmacological treatment only for chronic migraine with medication overuse after day-hospital withdrawal. Neurol Sci. 2009; 30 (Suppl. 1): S117-S119.
48. Gunreben-Stempfle B, Grießinger N, Lang E, Muehlhans B, Sittl R, Ulrich K,. Effectiveness of an intensive multidisciplinary headache treatment program. Headache. 2009; 49: 990-1000.
49. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC,. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002; 59: 1011-1014.
50. Linde M, Jonsson P, Hedenrud T,. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008; 118: 367-372.
51. Gaul C, van Doorn C, Webering N, etal. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: An observational study. J Headache Pain. 2011; 12: 475-483.
52. Silberstein SD, Dodick DW, Lindblad AS, etal. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007; 47: 170-180.
53. Aurora SK, Winner P, Freeman MC, etal. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011; 51: 1358-1373.
54. Srikiatkhachorn A, Tarasub N, Govitrapong P,. Effect of chronic analgesic exposure on the central serotonin system: A possible mechanism of analgesic abuse headache. Headache. 2000; 40: 343-350. (Pubitemid 30332035)
55. Supornsilpchai W, le Grand SM, Srikiatkhachorn A,. Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache. 2010; 50: 185-197.
56. Dobson CF, Tohyama Y, Diksic M, Hamel E,. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia. 2004; 24: 2-11. (Pubitemid 38085187)
57. Reuter U, Salomone S, Ickenstein GW, Waeber C,. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004; 24: 398-407. (Pubitemid 38621819)
58. Ayzenberg I, Obermann M, Leinweber K, etal. Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans. J Headache Pain. 2008; 9: 109-112.
59. Srikiatkhachorn A, Anthony M,. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia. 1996; 16: 423-426. (Pubitemid 26338473)
60. Bongsebandhu-phubhakdi S, Srikiatkhachorn A,. Pathophysiology of medication-overuse headache: Implications from animal studies. Curr Pain Headache Rep. 2012; 16: 110-115.
61. De Felice M, Porreca F,. Opiate-induced persistent pronociceptive trigeminal neural adaptations: Potential relevance to opiate-induced medication overuse headache. Cephalalgia. 2009; 29: 1277-1284.
62. De Felice M, Ossipov MH, Wang R, etal. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010; 133: 2475-2488.
63. Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P,. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: Relation with serotonin levels. Eur J Clin Pharmacol. 2008; 64: 1-8.
64. Cupini LM, Costa C, Sarchielli P, etal. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008; 30: 186-189.
65. Perrotta A, Arce-Leal N, Tassorelli C, etal. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012; 52: 1350-1361.
66. Akerman S, Holland PR, Goadsby PJ,. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther. 2007; 320: 64-71. (Pubitemid 46025720)
67. Grazzi L, Chiapparini L, Ferraro S, etal. Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: Clinical results and FMRI correlations. Headache. 2010; 50: 998-1004.
68. Ferraro S, Grazzi L, Mandelli ML, etal. Pain processing in medication overuse headache: A functional magnetic resonance imaging (FMRI) study. Pain Med. 2012; 13: 255-262.
69. Chiapparini L, Grazzi L, Ferraro S, etal. Functional-MRI evaluation of pain processing in chronic migraine with medication overuse. Neurol Sci. 2009; 30 (Suppl. 1): S71-S74.
70. Riederer F, Marti M, Luechinger R, etal. Grey matter changes associated with medication-overuse headache: Correlations with disease related disability and anxiety. World J Biol Psychiatry. 2012; 13: 517-525.
71. Ashina S, Bendtsen L, Ashina M, Magerl W, Jensen R,. Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia. 2006; 26: 940-948. (Pubitemid 44079718)
72. Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R,. Increased pain sensitivity is not a risk factor but a consequence of frequent headache: A population-based follow-up study. Pain. 2008; 137: 623-630. (Pubitemid 351981949)
73. Fernandez-de-Las-Penas C, Cuadrado ML, Arendt-Nielsen L, Ge HY, Pareja JA,. Increased pericranial tenderness, decreased pressure pain threshold, and headache clinical parameters in chronic tension-type headache patients. Clin J Pain. 2007; 23: 346-352. (Pubitemid 46650028)
74. Fernandez-de-Las-Penas C, Coppieters MW, Cuadrado ML, Pareja JA,. Patients with chronic tension-type headache demonstrate increased mechano-sensitivity of the supra-orbital nerve. Headache. 2008; 48: 570-577. (Pubitemid 351464677)
75. Grossi DB, Chaves TC, Gonçalves MC, etal. Pressure pain threshold in the craniocervical muscles of women with episodic and chronic migraine: A controlled study. Arq Neuropsiquiatr. 2011; 69: 607-612.
76. Filatova E, Latysheva N, Kurenkov A,. Evidence of persistent central sensitization in chronic headaches: A multi-method study. J Headache Pain. 2008; 9: 295-300.
77. Schwedt TJ, Krauss MJ, Frey K, Gereau RW,. Episodic and chronic migraineurs are hypersensitive to thermal stimuli between migraine attacks. Cephalalgia. 2011; 31: 6-12.
78. Kitaj MB, Klink M,. Pain thresholds in daily transformed migraine versus episodic migraine headache patients. Headache. 2005; 45: 992-998.
79. Okada-Ogawa A, Porreca F, Meng ID,. Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons. J Neurosci. 2009; 29: 15828-15835.
80. De Felice M, Ossipov MH, Wang R, etal. Triptan-induced latent sensitization: A possible basis for medication overuse headache. Ann Neurol. 2010; 67: 325-337.
81. De Felice M, Ossipov MH, Porreca F,. Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol. 2011; 24: 193-196.
82. Ayzenberg I, Obermann M, Nyhuis P, etal. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006; 26: 1106-1114. (Pubitemid 44199402)
83. Coppola G, Currà A, Di Lorenzo C, etal. Abnormal cortical responses to somatosensory stimulation in medication-overuse headache. BMC Neurol. 2010; 10: 126-134.
84. Perrotta A, Serrao M, Sandrini G, etal. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia. 2010; 30: 272-284.
85. Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, Pini LA,. Basal cutaneous pain threshold in headache patients. J Headache Pain. 2011; 12: 303-310.
86. Munksgaard SB, Bendtsen L, Jensen RH,. Modulation of central sensitisation by detoxification in MOH: Results of a 12-month detoxification study. Cephalalgia. 2013; 33: 444-453.
87. Cathcart S, Winefield AH, Lushington K, Rolan P,. Noxious inhibition of temporal summation is impaired in chronic tension-type headache. Headache. 2010; 50: 403-412.
88. Cooke L, Eliasziw M, Becker WJ,. Cutaneous allodynia in transformed migraine patients. Headache. 2007; 47: 531-539. (Pubitemid 46625254)
89. Latremoliere A, Woolf CJ,. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10: 895-926.
90. McMahon SB, Koltzenburg M,. Wall and Melzack's Textbook of Pain, 5th edn. Philadelphia, PA: Elsevier; 2006.